Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone

Active, not recruitingOBSERVATIONAL

Enrollment

565

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

January 3, 2028

Study Completion Date

January 3, 2028

Conditions

Pediatric Growth Hormone Deficiency

Interventions

DRUG

Ngenla

As provided in real world practice

Trial Locations (1)

Pfizer, Seoul